Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Can Intermittent Fasting Help You Lose Weight And Provide Other Health Benefits?

While it has been widely promoted as a weight loss strategy, research suggests that intermittent fasting may have broader benefits for overall health and well-being. A study published in the New England Journal of Medicine found that Intermittent Fasting can help lower blood pressure, improve insulin sensitivity, and reduce the risk of chronic diseases such…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

While it has been widely promoted as a weight loss strategy, research suggests that intermittent fasting may have broader benefits for overall health and well-being. A study published in the New England Journal of Medicine found that Intermittent Fasting can help lower blood pressure, improve insulin sensitivity, and reduce the risk of chronic diseases such as diabetes and heart disease.

Another study in the journal Cell Metabolism found that Intermittent Fasting can increase the production of a protein called brain-derived neurotrophic factor (BDNF), which is essential for the growth and maintenance of neurons in the brain.

Despite these promising findings, new research found that intermittent fasting may not be as beneficial for weight loss as previously thought while another study found that that it does not bring the same health benefits as other weight loss programs.

These new findings leave lots of questions unanswered. Does intermittent fasting help with weight loss and provide other health benefits or is it just another fad diet targeted to those who are looking to lose weight? Kimberly Gomer, director of nutrition at Body Beautiful Miami, is a leading nutritional expert in weight loss and medical nutrition for over 2 decades. She brings her years of experience to the discussion and offers her in-depth analysis of this dietary strategy.

Kim’s Thoughts:

I love this article on intermittent fasting because it brings to light an unknown idea for a lot of people. I do believe from the science, looking at the science, that there is benefit to time-restricted eating. So, you’re fasting for a certain amount of time and then you’re eating. The idea that immune autophagy maintaining muscle mass is a possibility with fasting.

But the exciting part for me as a nutritionist is the stability of blood sugar. Because high insulin levels, high blood sugars are a huge problem in the United States—we are looking at one in three people with prediabetes. We are looking at one in 10 people with diabetes, and we are looking at one in five people who don’t even know they have it.

So, this idea that we can lower insulin levels and we can stabilize blood sugar and do it through an intermittent fasting lifestyle, is amazing. And part of the science behind it is that when you are not eating, be it sleeping or just not eating, your insulin is very low. It’s the lowest when you’re not eating so allowing for a time that you are not eating in your day to be extended and eating only in a certain window, there are a lot of health benefits.

The problem that I see with some of these articles and understanding how they would apply to you as an individual is the fasting times are all over the place. Are you fasting for 18 hours a day? Are you fasting for 16 hours a day? Are you fasting for 12 hours a day?

Is your eating window very short? One to three hours or long eight hours. So, this idea of what is the best fasting and eating window is still not clear in some of the research, and more important in my mind, yes, intermittent fasting is a great tool. I use it in my private practice as a dietician with a lot of success.

But one thing that has to come with it is what are you eating? We live in a world of obesogenic food, highly processed, unhealthy food. So, some of my clients actually think, some people think well I can fast for 20 hours and for four hours I can go and eat fast food and eat junk, and I’m going to be healthy and thin. Not true.

So, I love intermittent fasting, I think we need more and more research about it. I think people need to be clear about what will work for them, how the tool can work for them as an individual, and more importantly, be clear about what they’re actually eating during their window. Again, I’m going to say I think that intermittent fasting is an awesome tool.

I’m so happy to see research being published. More research needs to be done and I think it can be very useful for a lot of people. Thank you.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512